Predictive biomarkers and practical considerations in the management of carfilzomib-associated cardiotoxicity

Leuk Lymphoma. 2018 Aug;59(8):1981-1985. doi: 10.1080/10428194.2017.1403020. Epub 2018 Jan 8.

Nikoletta Lendvai^{1

2}, Ioanna Tsakos¹, Sean M Devlin³, Wendy L Schaffer^{2

4}, Hani Hassoun^{1

2}, Alexander M Lesokhin^{1

2}, Heather Landau^{2

5}, Neha Korde^{1

2}, Sham Mailankody^{1

2}, Eric Smith^{1

2}, David J Chung^{2

5}, Guenther Koehne^{2

5}, Gunjan L Shah^{2

5}, Aeri Alexander¹, Minal Patel⁶, Andrea Ballagi⁷, Ida Grundberg⁷, Sergio A Giralt^{2

5}, Ola Landgren^{1

2}

¹ a Department of Medicine , Myeloma Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
² b Department of Medicine , Weill Medical College of Cornell University , New York , NY , USA.
³ c Department of Biostatistics and Epidemiology , Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
⁴ d Department of Medicine , Cardiology Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
⁵ e Department of Medicine , Adult Bone Marrow Transplant Service, Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
⁶ f Sloan Kettering Institute , Memorial Sloan-Kettering Cancer Center , New York , NY , USA.
⁷ g Olink Bioscience , Uppsala , Sweden.

No abstract available

Publication types